Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620267 | 0.85 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL1782399 | 0.85 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL1781303 | 0.85 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL14582391 | 0.84 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL4619857 | 0.84 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL4620975 | 0.84 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL1779006 | 0.83 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL14582309 | 0.83 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL1780605 | 0.83 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD | |
| SCHEMBL4620534 | 0.82 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885701-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | Novartis Vaccines and Diagnostics, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006113498-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | HSP90AA1 3373/4885HSP90AB1 3036/4885MAPT 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.